Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
2,841.00
-70.20 (-2.41%)
Apr 28, 2025, 1:30 PM IST
Dr. Lal PathLabs Revenue
In the fiscal year ending March 31, 2025, Dr. Lal PathLabs had annual revenue of 25.55B INR with 14.74% growth. Dr. Lal PathLabs had revenue of 6.28B in the quarter ending March 31, 2025, with 15.21% growth.
Revenue
25.55B
Revenue Growth
+14.74%
P/S Ratio
9.86
Revenue / Employee
6.00M
Employees
4,099
Market Cap
242.58B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 25.55B | 3.28B | 14.74% |
Mar 31, 2024 | 22.27B | 2.10B | 10.40% |
Mar 31, 2023 | 20.17B | -705.26M | -3.38% |
Mar 31, 2022 | 20.87B | 5.06B | 32.01% |
Mar 31, 2021 | 15.81B | 2.51B | 18.86% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 516.03B |
Divi's Laboratories | 90.78B |
Cipla | 267.20B |
Mankind Pharma | 116.41B |
Apollo Hospitals Enterprise | 211.46B |
Zydus Lifesciences | 222.47B |
Aurobindo Pharma | 309.22B |
Alkem Laboratories | 127.57B |
Dr. Lal PathLabs News
- 2 days ago - Dr. Lal PathLabs Q4 FY25: Revenue up 10.48% to 602.6 crore, Net profit surges 81% YoY - Business Upturn
- 6 months ago - Dr Lal Path Labs stock jumps 3.46% after strong Q2 earnings and positive brokerage calls - Business Upturn
- 6 months ago - Dr Lal Path Labs share price: Buy, Sell, or Hold? Check what brokerages are saying - Business Upturn
- 6 months ago - UBS maintains buy call on Dr LalPath Labs, expects 7.7% upside in share price - Business Upturn
- 6 months ago - Dr Lal PathLabs Q2 FY25: Revenue up 9.8% YoY to ₹660.2 crore, net profit rises 18.1% YoY to ₹130.8 crore - Business Upturn
- 6 months ago - Nomura maintains ‘Buy’ on Dr Lal PathLabs, target price set at ₹3,720 - Business Upturn